LU91585I2 - Degarelix, éventuellement un sel pharmaceutiquement acceptable, tel que l'acétate (FIRMAGON) - Google Patents

Degarelix, éventuellement un sel pharmaceutiquement acceptable, tel que l'acétate (FIRMAGON)

Info

Publication number
LU91585I2
LU91585I2 LU91585C LU91585C LU91585I2 LU 91585 I2 LU91585 I2 LU 91585I2 LU 91585 C LU91585 C LU 91585C LU 91585 C LU91585 C LU 91585C LU 91585 I2 LU91585 I2 LU 91585I2
Authority
LU
Luxembourg
Prior art keywords
firmagon
degarelix
acetate
optionally
pharmaceutically acceptable
Prior art date
Application number
LU91585C
Other languages
English (en)
French (fr)
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25273352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91585(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of LU91585I2 publication Critical patent/LU91585I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/11—Gonadotropin; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
LU91585C 1997-04-11 2009-07-17 Degarelix, éventuellement un sel pharmaceutiquement acceptable, tel que l'acétate (FIRMAGON) LU91585I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/837,042 US5925730A (en) 1997-04-11 1997-04-11 GnRH antagonists
PCT/US1998/007438 WO1998046634A1 (en) 1997-04-11 1998-04-13 GnRH ANTAGONISTS BEING MODIFIED IN POSITIONS 5 AND 6

Publications (1)

Publication Number Publication Date
LU91585I2 true LU91585I2 (fr) 2009-09-17

Family

ID=25273352

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91585C LU91585I2 (fr) 1997-04-11 2009-07-17 Degarelix, éventuellement un sel pharmaceutiquement acceptable, tel que l'acétate (FIRMAGON)

Country Status (36)

Country Link
US (2) US5925730A (enExample)
EP (1) EP1003774B1 (enExample)
JP (2) JP4249806B2 (enExample)
KR (1) KR100519421B1 (enExample)
CN (1) CN1230442C (enExample)
AR (1) AR011217A1 (enExample)
AT (1) ATE319736T1 (enExample)
AU (1) AU728642B2 (enExample)
BR (1) BR9808523B1 (enExample)
CA (1) CA2286190C (enExample)
CY (2) CY1108063T1 (enExample)
CZ (1) CZ299097B6 (enExample)
DE (2) DE69833751T2 (enExample)
DK (1) DK1003774T3 (enExample)
EE (1) EE03974B1 (enExample)
ES (1) ES2260833T3 (enExample)
FR (1) FR09C0028I2 (enExample)
HR (1) HRP980197B1 (enExample)
HU (1) HU224836B1 (enExample)
IL (1) IL132303A0 (enExample)
LU (1) LU91585I2 (enExample)
MY (1) MY114811A (enExample)
NL (1) NL300395I2 (enExample)
NO (2) NO324991B1 (enExample)
NZ (1) NZ500142A (enExample)
PL (1) PL194509B1 (enExample)
PT (1) PT1003774E (enExample)
RU (1) RU2199549C2 (enExample)
SI (1) SI1003774T1 (enExample)
SK (1) SK285381B6 (enExample)
TR (1) TR199902956T2 (enExample)
TW (1) TW505658B (enExample)
UA (1) UA58547C2 (enExample)
UY (1) UY24958A1 (enExample)
WO (1) WO1998046634A1 (enExample)
ZA (1) ZA983062B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
US5977302A (en) * 1997-11-20 1999-11-02 Ortho-Mcneil Pharmaceutical, Inc. Liquid phase process for the preparation of GnRH peptides
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
IL147138A0 (en) * 2001-12-17 2002-08-14 Yeda Res & Dev Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
DE20321887U1 (de) 2003-11-10 2012-01-20 Allergan, Inc. Arzneimittel umfassend niedrige Dosierungen von Desmopressin
CA2866501A1 (en) 2003-11-10 2005-05-26 Allergan, Inc. Pharmaceutical compositions including low dosages of desmopressin
CN101037472B (zh) * 2006-03-14 2013-03-27 中国人民解放军军事医学科学院毒物药物研究所 具有低组胺释放作用的促黄体生成素释放激素拮抗剂
WO2007117706A2 (en) * 2006-04-07 2007-10-18 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
TWI442932B (zh) 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
CN102046192B (zh) * 2008-05-07 2014-11-19 默里昂研究Ⅲ有限公司 GnRH相关化合物的组合物及制备方法
WO2010099255A1 (en) * 2009-02-25 2010-09-02 Merrion Research Iii Limited Composition and drug delivery of bisphosphonates
RU2515555C2 (ru) * 2009-04-24 2014-05-10 Полипептид Лэборэторис А/С Способ получения дегареликса
TWI508734B (zh) * 2009-05-01 2015-11-21 Ferring Int Ct Sa 用於前列腺癌之治療的組成物
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
WO2011066386A1 (en) 2009-11-25 2011-06-03 Novetide, Ltd. Process for production of degarelix
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (en) * 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
ES2617336T3 (es) 2010-10-27 2017-06-16 Ferring B.V. Procedimiento para la fabricación de degarelix y sus productos intermedios
EP2447276A1 (en) * 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
AU2011348220B2 (en) 2010-12-22 2017-09-07 The Salk Institute For Biological Studies Cyclic CRF antagonist peptides
WO2012094598A2 (en) 2011-01-07 2012-07-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
WO2013104745A1 (en) 2012-01-13 2013-07-18 Ferring Bv Pharmaceutical composition
JP6226966B2 (ja) 2012-06-01 2017-11-08 フェリング ベスローテン フェンノートシャップ デガレリクスの製造
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
EP3390427B1 (en) 2015-12-17 2021-08-25 Fresenius Kabi iPSUM S.r.l. Process for the manufacture of degarelix and its intermediates
CN107778355B (zh) * 2016-08-25 2021-04-20 成都圣诺生物制药有限公司 一种合成西曲瑞克的方法
WO2019110688A1 (en) 2017-12-05 2019-06-13 Ferring B.V. A composition comprising degarelix for use in the treatment of breast cancer
EP4004001B1 (en) 2019-07-29 2025-09-03 Sunshine Lake Pharma Co., Ltd. Substituted pyrimidinedione compounds and uses thereof
US11332495B2 (en) 2019-09-21 2022-05-17 RK Pharma Solutions LLC Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix
CN114456236A (zh) * 2020-11-09 2022-05-10 深圳市健翔生物制药有限公司 一种地加瑞克乙酰化杂质的制备方法
WO2023072284A1 (zh) 2021-11-01 2023-05-04 山东绿叶制药有限公司 促性腺素释放激素拮抗剂及其制备方法和应用
WO2026068660A1 (en) 2024-09-26 2026-04-02 Ferring B.V. Lipidated gonadotropin releasing hormone analogues

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4547370A (en) * 1983-11-29 1985-10-15 The Salk Institute For Biological Studies GnRH Antagonists
US4508921A (en) * 1984-06-28 1985-04-02 Merck & Co., Inc. Process for preparation of alpha-alkyl amino acids
US5073624A (en) * 1985-04-09 1991-12-17 Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US4866160A (en) * 1985-04-09 1989-09-12 The Administrators Of The Tulane Educational Fund Therapeutic decapeptides
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
US4935491A (en) * 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
US5171835A (en) * 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
US5296468A (en) * 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
AU1371892A (en) * 1991-04-25 1992-12-21 Romano Deghenghi Luteinizing hormone releasing hormone antagonist peptides
JP3568952B2 (ja) * 1992-12-18 2004-09-22 アボット・ラボラトリーズ ５位及び６位に修飾アミノアシル残基を有するｌｈｒｈ拮抗薬
IL108509A0 (en) * 1993-02-22 1994-05-30 Salk Inst For Biological Studi GnRH antagonist peptides
RU2084458C1 (ru) * 1993-05-27 1997-07-20 Институт высокомолекулярных соединений РАН Декапептид, обладающий противоопухолевой активностью
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists

Also Published As

Publication number Publication date
PL336213A1 (en) 2000-06-05
EE9900479A (et) 2000-06-15
HU224836B1 (en) 2006-03-28
PL194509B1 (pl) 2007-06-29
DE122009000033I2 (de) 2011-07-21
ATE319736T1 (de) 2006-03-15
ES2260833T3 (es) 2006-11-01
MY114811A (en) 2003-01-31
KR20010006233A (ko) 2001-01-26
CY1108063T1 (el) 2012-01-25
TW505658B (en) 2002-10-11
CZ358699A3 (cs) 2000-06-14
EE03974B1 (et) 2003-02-17
BR9808523B1 (pt) 2010-02-09
HRP980197A2 (en) 1999-02-28
CN1230442C (zh) 2005-12-07
FR09C0028I1 (enExample) 2009-09-25
CY2009008I2 (el) 2012-01-25
HUP0002704A3 (en) 2003-08-28
JP2005120101A (ja) 2005-05-12
WO1998046634A1 (en) 1998-10-22
BR9808523A (pt) 2000-05-23
SK139699A3 (en) 2000-11-07
SK285381B6 (sk) 2006-12-07
HUP0002704A2 (hu) 2000-12-28
EP1003774B1 (en) 2006-03-08
NO2009016I1 (no) 2009-08-10
NO994906L (no) 1999-12-13
CY2009008I1 (el) 2012-01-25
CA2286190A1 (en) 1998-10-22
CZ299097B6 (cs) 2008-04-23
NO324991B1 (no) 2008-01-14
FR09C0028I2 (fr) 2010-06-11
KR100519421B1 (ko) 2005-10-06
NO2009016I2 (no) 2014-08-25
TR199902956T2 (xx) 2000-08-21
JP4249806B2 (ja) 2009-04-08
EP1003774A1 (en) 2000-05-31
HK1025104A1 (en) 2000-11-03
DE69833751D1 (de) 2006-05-04
UA58547C2 (uk) 2003-08-15
NZ500142A (en) 2001-10-26
CA2286190C (en) 2007-01-09
DE69833751T2 (de) 2006-11-09
CN1259959A (zh) 2000-07-12
DE122009000033I1 (de) 2009-09-17
US6214798B1 (en) 2001-04-10
JP3645255B1 (ja) 2005-05-11
AR011217A1 (es) 2000-08-02
UY24958A1 (es) 2001-03-16
US5925730A (en) 1999-07-20
AU6969898A (en) 1998-11-11
HRP980197B1 (en) 2002-08-31
NO994906D0 (no) 1999-10-08
SI1003774T1 (sl) 2006-08-31
RU2199549C2 (ru) 2003-02-27
NL300395I2 (nl) 2010-01-04
DK1003774T3 (da) 2006-07-03
AU728642B2 (en) 2001-01-11
IL132303A0 (en) 2001-03-19
JP2001523229A (ja) 2001-11-20
NL300395I1 (nl) 2009-09-01
ZA983062B (en) 1998-10-20
PT1003774E (pt) 2006-05-31

Similar Documents

Publication Publication Date Title
LU92699I2 (fr) Bazédoxifène, éventuellement sous la forme d'un sel pharmaceutiquement, acceptable tel que le sel d'acétate, et d'estrogènes conjugués
FI20010420L (fi) Puhelun ylläpito paikannuksen aikana
IT1303740B1 (it) Piedistallo ad assorbimento d'urto per sedie.
AU6088200A (en) Novel vasodilator cannabinoid analogs
IL125281A0 (en) Novel fungicidal composition comprising a 2-imidazolin-5-one
ITTO910894A0 (it) "un procedimento per preparare dipeptidi".
ZA967359B (en) Substituted benzothiazoles as crop protection agents.
IT1268094B1 (it) Struttura d'arresto di un cavalletto per un motoveicolo a due o tre ruote.
FI990032A7 (fi) Okulaarisia hypotensiivisiä aktiivisia yhdisteitä
FI943872A0 (fi) 2,6-metano-2H-kinditsiinijohdannainen 5-HT3-reseptoriantagonistina
NZ320449A (en) Dunnione as a fungicidal composition
FR2685212B1 (fr) Un systeme de protection des espaces boises contre l'incendie.
DK0741527T3 (da) Beskyttelsessportshovedbeklædning
ITFI940168A0 (it) Macchina di raccolta come macchina per vendemmiare
IT1304182B1 (it) Struttura portante per un filatoio.
ITMI930017A0 (it) Composizione polimerizzabile per l'impreganzione di un supporto tessile, avente elevate caratteristiche tixotropiche
FR2735103B1 (fr) Support d'elements d'echafaudages.
IT1284733B1 (it) Procedimento per la produzione di un preparato per risotto
KR920014295U (ko) 음성, 영상잭 보호커버
AP9901498A0 (en) Novel fungicidal composition comprising a 2-imidazolin-5-one
ZA919966B (en) Novel hydantoin compounds.
SE9001466D0 (sv) Stoeldskydd, saerskilt foer skor
IT241008Y1 (it) Struttura portante per un'amaca
IT233304Y1 (it) Supporto polifunzionale per operazioni di stirerie.
ITRM960097V0 (it) Portabebe' orizzontale a tracolla.